Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time

Inhibitor (neutralizing antibodies) development remains the most significant complication in patients with severe congenital hemophilia A receiving exogenous factor VIII (FVIII). Although our understanding of the pathophysiology of inhibitor development has advanced, the knowledge gained has not yet translated into a robust decline in incidence, with the overall risk remaining at ˜30%. Immune Tolerance Induction (ITI) is the only current method to successfully eradicate an inhibitor and achieve long-term tolerance.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research